The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer.

Abstract:

BACKGROUND:Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therapy, we report on the outcome of 11 patients treated with IPM after sunitinib failure. PATIENTS AND METHODS:Eleven patients with progression of disease on sunitinib therapy were treated with 4, monthly cycles of monthly IPM. RESULTS:Nine out of 11 patients progressed during IPM therapy. The median time to progression was 1.4 months (95% CI: 0.7-2.1 months), while the overall survival was 4.2 months (95% CI: 0.9-2.3). Overall 10 patients have died of progressive renal cancer. One patient had a radiological response to therapy and remains progression free 11 months after treatment. Four of the 10 patients required a dose reduction for grade 3 or 4 toxicities. CONCLUSIONS:IPM alone does not appear to benefit patients with MCRC who previously progressed during sunitinib therapy. The median progression-free survival and overall survival for these patients is short.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Powles T,McFaul S,Stebbing J,Wilson P,Oliver T,Tranter N,Shamash J

doi

10.2147/ott.s3590

subject

Has Abstract

pub_date

2008-09-01 00:00:00

pages

35-9

issn

1178-6930

journal_volume

1

pub_type

杂志文章
  • Differential expression of two activating transcription factor 5 isoforms in papillary thyroid carcinoma.

    abstract:BACKGROUND:Activating transcription factor 5 (ATF5) is a member of the activating transcription/cAMP response element-binding protein family of basic leucine zipper proteins that plays an important role in cell survival, differentiation, proliferation, and apoptosis. The ATF5 gene generates two transcripts: ATF5 isofor...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113194

    authors: Vicari L,La Rosa C,Forte S,Calabrese G,Colarossi C,Aiello E,Salluzzo S,Memeo L

    更新日期:2016-10-11 00:00:00

  • CircDDX42 Accelerates the Development of Pancreatic Cancer via miR-613/ID4/PI3K/AKT Axis.

    abstract:Background:Pancreatic cancer (PC) is one of the fatal cancers globally. CircDEAD-box helicase 42 (circDDX42) has been reported to play an oncogenic role in many cancers. The purpose of our study was to explore the relationship between circDDX42 and PC development and the potential mechanism by which circDDX42 modulatin...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S233000

    authors: Yan Z,Yin H,Lin G

    更新日期:2020-10-28 00:00:00

  • The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy.

    abstract::Erastin was initially discovered as a small molecule compound that selectively kills tumor cells expressing ST and RASV12 and was later widely investigated as an inducer of ferroptosis. Ferroptosis is a recently discovered form of cell death caused by peroxidation induced by the accumulation of intracellular lipid rea...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S254995

    authors: Zhao Y,Li Y,Zhang R,Wang F,Wang T,Jiao Y

    更新日期:2020-06-11 00:00:00

  • Cervical Cancer: Emerging Immune Landscape and Treatment.

    abstract::Immune cells are essential for defending the body's balance and have increasingly been implicated in controlling tumor growth. In cervical cancer (CC), the immune landscape is extensively connected with human papillomavirus (HPV) status. Recent insights from studies have revealed that as a result of infection with HPV...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S264312

    authors: Guo L,Hua K

    更新日期:2020-08-12 00:00:00

  • The NRF2/KEAP1 Pathway Modulates Nasopharyngeal Carcinoma Cell Radiosensitivity via ROS Elimination.

    abstract:Purpose:Radioresistance is a vital obstacle for the prognosis of human nasopharyngeal carcinoma (NPC), but the underlying mechanism is still unknown. Here, we explored the role of the NRF2/KEAP1 pathway in radioresistance of NPC cell lines. Materials and Methods:We selected NPC cell lines CNE-1 and CNE-2, treated them...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S260169

    authors: Zhou J,Ding J,Ma X,Zhang M,Huo Z,Yao Y,Li D,Wang Z

    更新日期:2020-09-11 00:00:00

  • Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell lines.

    abstract:PURPOSE:One of the most challenging aspects of breast carcinoma chemotherapy is the rapid acquirement of drug resistance. Improving the sensitivity to chemotherapeutic drugs is very important for successful treatment. Mus81 plays an important role in maintaining the stability of the genome and DNA repair. However, rece...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S64339

    authors: Qian Y,Liu Y,Yan Q,Lv J,Ni X,Wu Y,Dong X

    更新日期:2014-10-21 00:00:00

  • Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer.

    abstract:Aim:We aimed to assess the role of 21-gene recurrence score (RS) in the decision-making for surgical treatment in early stage breast cancer and compared the outcomes between breast-conserving surgery (BCS) and mastectomy (MAST) among various 21-gene RS groups. Methods:We included patients with stage T1-2M0M0 and estro...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S199625

    authors: Wu SG,Zhang WW,Wang J,Dong Y,Chen YX,He ZY

    更新日期:2019-03-19 00:00:00

  • Profile of selumetinib and its potential in the treatment of melanoma.

    abstract::The mitogen-activated protein kinase (MAPK) pathway is a critical oncogenic driver signal in a number of malignancies. The discovery of activating mutations in the MAPK pathway has led to the development of MAPK pathway inhibitors. Selumetinib is a potent and selective inhibitor of MEK1 and MEK2, which are essential d...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S51596

    authors: Kim DW,Patel SP

    更新日期:2014-09-19 00:00:00

  • Exploring targeted therapy of osteosarcoma using proteomics data.

    abstract::Despite multimodal therapeutic treatments of osteosarcoma (OS), some patients develop resistance to currently available regimens and eventually end up with recurrent or metastatic outcomes. Many attempts have been made to discover effective drugs for improving outcome; however, due to the heterogeneity of the disease,...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S119993

    authors: Chaiyawat P,Settakorn J,Sangsin A,Teeyakasem P,Klangjorhor J,Soongkhaw A,Pruksakorn D

    更新日期:2017-02-01 00:00:00

  • Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.

    abstract::Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies. Since 2011, four new classes of medications with unique mechanisms of action have been approved, which allow melanoma to be treated at many different stages in i...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S171693

    authors: Sun J,Zager JS,Eroglu Z

    更新日期:2018-12-14 00:00:00

  • Investigation Of Small Molecular Substances As Potential Biomarkers For Discrimination Of Gastric Tumor.

    abstract:Background:Gastric tumor (GT) is associated with high morbidity and mortality, with surgery among the most effective treatment methods. Accurate interoperative determination of the tumor margin is crucial. Methods:In this study, using internal extractive electrospray ionization-MS, mass spectral data of GT and gastric...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S221589

    authors: Zhang J,Gao Q,Luo X,Zhang W,Wang N,Wei Y

    更新日期:2019-10-17 00:00:00

  • Prognostic significance of circulating laminin gamma2 for early-stage non-small-cell lung cancer.

    abstract:BACKGROUND:Laminin gamma2 (Ln-γ2) chain, a distinctive subunit of heterotrimeric laminin-332, is frequently upregulated in carcinomas and is of great importance in cell migration and invasion. Despite this, the status of circulating Ln-γ2 in lung cancer patients is still uncertain. PATIENTS AND METHODS:In this retrosp...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S105732

    authors: Teng Y,Wang Z,Ma L,Zhang L,Guo Y,Gu M,Wang Z,Wang Y,Yue W

    更新日期:2016-07-07 00:00:00

  • Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.

    abstract:BACKGROUND:Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaïv...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S62639

    authors: Tseng JS,Yang TY,Chen KC,Hsu KH,Yu CJ,Liao WY,Tsai CR,Tsai MH,Yu SL,Su KY,Chen JJ,Chen HY,Chang GC

    更新日期:2014-05-23 00:00:00

  • Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.

    abstract::Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death l...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S259308

    authors: Gullapalli S,Remon J,Hendriks LEL,Lopes G

    更新日期:2020-07-14 00:00:00

  • Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.

    abstract::Background: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer morbidity and mortality worldwide. In the present study, we identified novel biomarkers associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeutic approaches for NSCLC. Methods: The microarray datasets of...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S198621

    authors: Wu Q,Zhang B,Sun Y,Xu R,Hu X,Ren S,Ma Q,Chen C,Shu J,Qi F,He T,Wang W,Wang Z

    更新日期:2019-05-13 00:00:00

  • Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips.

    abstract:Background:The diagnosis rate of early stage esophageal squamous cell carcinoma (ESCC) is low due to the lack of specific tumor markers. Seeking for these markers is beneficial to improve the early diagnosis rate and the prognosis of patients. This study profiles the differentially expressed proteins of early stage ESC...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S171242

    authors: Tong Q,Wang XL,Li SB,Yang GL,Jin S,Gao ZY,Liu XB

    更新日期:2018-09-12 00:00:00

  • Downregulation of ribophorin II suppresses tumor growth, migration, and invasion of nasopharyngeal carcinoma.

    abstract:Background:It has been reported that ribophorin II (RPN2) expression is increased in many cancers, but the role of RPN2 in nasopharyngeal carcinoma (NPC) remains unclear. Patients and methods:This study found that the expression of RPN2 is increased dramatically in NPC tissues of patients compared with that in the adj...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S158355

    authors: Hong F,Li Y,Ni H,Li J

    更新日期:2018-06-15 00:00:00

  • circZNF609 promotes the proliferation and migration of gastric cancer by sponging miR-483-3p and regulating CDK6.

    abstract:Objective:To explore the regulatory effects of circZNF609 on proliferative and migratory capacities of gastric cancer (GC) and its underlying mechanism. Methods:Expression level of circZNF609, CDK6 and miR-483-3p in GC tissues and cells were detected qRT-PCR verification. CCK-8 and transwell assay were conducted the c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S193031

    authors: Wu W,Wei N,Shao G,Jiang C,Zhang S,Wang L

    更新日期:2019-10-04 00:00:00

  • Knockdown of Circular RNA Hsa_circ_0000714 Can Regulate RAB17 by Sponging miR-370-3p to Reduce Paclitaxel Resistance of Ovarian Cancer Through CDK6/RB Pathway.

    abstract:Purpose:Paclitaxel resistance in ovarian cancer has become an urgent clinical problem. This study investigated the regulatory effects of RAB17 on the non-coding RNA network of the paclitaxel-resistant ovarian cancer cell A2780/PTX. Methods:Microarray analysis was used to identify differentially expressed genes in pacl...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S285153

    authors: Guo M,Li S,Zhao X,Yuan Y,Zhang B,Guan Y

    更新日期:2020-12-24 00:00:00

  • Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.

    abstract::Despite the prominent effects of BCR-ABL tyrosine kinase inhibitors (TKI) therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) and thus low incidence of blastic transformation, blast phase (BP)-CML remains a major therapeutic challenge in the TKI era. The "gatekeeper" mutation T315I in BCR-ABL1 kin...

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S232102

    authors: Zhou L,Shi H,Shi W,Yang L,Zhang Y,Xu M,Chen X,Zhu Y,Mu H,Wan X,Yang Z,Zeng Y,Liu H

    更新日期:2019-12-13 00:00:00

  • HMGA2 Gene rs8756 A>C Polymorphism Reduces Neuroblastoma Risk in Chinese Children: A Four-Center Case-Control Study.

    abstract:Background:Neuroblastoma, mainly affecting children, is a lethal malignancy arising from the developing sympathetic nervous system. The genetic etiology of neuroblastoma remains mostly obscure. High mobility group AT-hook 2 (HMGA2), an oncogenic gene, is up-regulated in many tumors. Single nucleotide polymorphisms (SNP...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S229975

    authors: Liu J,Hua RX,Cheng Y,Zhu J,Zhang J,Cheng J,Zhou H,Xia H,Bian J,He J

    更新日期:2020-01-15 00:00:00

  • Expression of PER, CRY, and TIM genes for the pathological features of colorectal cancer patients [Retraction].

    abstract::[This retracts the article on p. 1997 in vol. 9, PMID: 27103825.][This retracts the article on p. 841 in vol. 28.]. ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,撤回出版物

    doi:10.2147/OTT.S121862

    authors:

    更新日期:2016-09-20 00:00:00

  • Association of estrogen receptor α PvuII and XbaI polymorphisms with prostate cancer susceptibility and risk stratification: a meta-analysis from case-control studies.

    abstract:BACKGROUND:Studies on the association between two single nucleotide polymorphisms (SNPs) in estrogen receptor α (ERα), PvuII (rs2234693 T>C) and XbaI (rs9340799 A>G), and the prostate cancer risk are inconsistent. Therefore, we performed a meta-analysis to derive a more accurate estimation of this relationship. METHOD...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S132419

    authors: Zhao Y,Zheng X,Zhang L,Hu Q,Guo Y,Jiang H,Shi S,Zhang X

    更新日期:2017-06-29 00:00:00

  • Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme.

    abstract:BACKGROUND:MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated. PATIENTS AND METHODS:Our study enrolled 86 resected samples of GBM in three medical ce...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S95831

    authors: Hou A,Zhao L,Zhao F,Wang W,Niu J,Li B,Zhou Z,Zhu D

    更新日期:2016-01-13 00:00:00

  • Prognostic value of FOXQ1 in patients with malignant solid tumors: a meta-analysis.

    abstract:BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S130905

    authors: Cui X,Zhang J,Lv J,Yan Y,Liu X,Wang J,Lv Y,Zhang J

    更新日期:2017-03-23 00:00:00

  • Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.

    abstract::The study is designed to explore the correlations of microvascular blood flow of contrast-enhanced ultrasound (CEUS) and hepatocyte growth factor (HGF)/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma (HCC). One hundred and eighteen patients pathological...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S113353

    authors: Zhuang PH,Xu L,Gao L,Lu W,Ruan LT,Yang J

    更新日期:2017-02-14 00:00:00

  • Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum].

    abstract::[This corrects the article DOI: 10.2147/OTT.S262089.]. ...

    journal_title:OncoTargets and therapy

    pub_type: 已发布勘误

    doi:10.2147/OTT.S292577

    authors:

    更新日期:2020-11-27 00:00:00

  • Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.

    abstract:Aim:The use of bevacizumab in combination therapy is an emerging trend in metastatic colorectal cancer treatment. However, the clinical value of different combination types remains under debate. Thus, a meta-analysis of randomized controlled trials (RCTs) comparing bevacizumab-based combination therapy with monotherapy...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S171724

    authors: Xu R,Xu C,Liu C,Cui C,Zhu J

    更新日期:2018-12-04 00:00:00

  • The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.

    abstract:Background:Breast cancer resistance protein BCRP, belonging to superfamily G of the adenosine triphosphate-binding cassette (ABC) transporters, is an efflux pump and plays a critical role in protecting cells against xenobiotics and toxic compounds including (pro)carcinogens. BCRP is expressed in many tissues, including...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S195245

    authors: Niebudek K,Balcerczak E,Mirowski M,Pietrzak J,Zawadzka I,Żebrowska-Nawrocka M

    更新日期:2019-02-27 00:00:00

  • Helicobacter pylori CagA Protein Attenuates 5-Fu Sensitivity of Gastric Cancer Cells Through Upregulating Cellular Glucose Metabolism.

    abstract:Introduction:Gastric cancer (GC) is one of the most malignancies leading to human mortality due to its development, progress, metastasis and poor prognosis, despite the development of remarkable chemotherapy and surgery. The 5-fluorouracil (5-Fu) is an effective anti-gastric cancer agent. However, a fraction of GC patie...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S230875

    authors: Gao S,Song D,Liu Y,Yan H,Chen X

    更新日期:2020-07-01 00:00:00